About / News & Updates

Fibrosis-specific substrates provide a disease-relevant in-vitro testing platform to inform decision-making in early-stage drug discovery. Through the development of fibrosis-specific in-vitro substrates, Xylyx Bio aims to support drug discovery and development for fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and non-alcoholic steatohepatitis (NASH).

Xylyx Bio announced that it has joined the Advanced Regenerative Manufacturing Institute (ARMI), a public-private Manufacturing USA initiative that supports the manufacturing of engineered tissues and tissue-related technologies, with the goal to focus on accelerating the standardization and commercialization of tissue-specific extracellular matrix biomaterials for regenerative medicine and tissue engineering.

Xylyx Bio announced partnerships with 9 international distributors to meet growing demand. Additional distributors provide scientists working in drug screening, cancer research, 3D cell models and toxicology with the ability to improve the human relevance of in vitro cell models.

East River BioSolutions, a biotech company specializing in cell-specific extracellular matrix biomaterials, today announced its rebrand to Xylyx Bio. The new branding underscores the Company’s focus on accelerating science for improved human health.

East River BioSolutions is proud to announce that it has been awarded SBIR Phase I grant from the NIIH. The award will support further development of a fibrotic lung-specific cell culture substrate that will allow scientists to build more physiologically relevant in vitro models of IPF.